Immunoaffinity chromatographic isolation of prostate-specific antigen from seminal plasma for capillary electrophoresis analysis of its isoforms

Analytica Chimica Acta

Volumn 820, Issue , 2014, Pages 47-55

  Garrido Medina, Raul ^a   Farina Gomez, Noemi ^a   Diez Masa, Jose Carlos ^a   De Frutos, Mercedes ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Affinity chromatography; Capillary electrophoresis; Glycoform; Prostate specific antigen; Purification

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BIOMARKERS; BODY FLUIDS; CAPILLARY ELECTROPHORESIS; DISEASES; ESTERIFICATION; GLYCOSYLATION; PROTEINS; UROLOGY;

CAPILLARY ELECTROPHORESIS ANALYSIS; CHROMATOGRAPHIC ISOLATION; CORRECTED PEAK AREAS; GLYCOFORMS; IMMUNOAFFINITY CHROMATOGRAPHY; PATHOLOGICAL CONDITIONS; PHOSPHATE-BUFFERED SALINES; PROSTATE SPECIFIC ANTIGEN;

PURIFICATION;

ISOPROTEIN; PROPIONIC ACID; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN PURIFICATION; ARTICLE; CAPILLARY ELECTROPHORESIS; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REPRODUCIBILITY; SEMINAL PLASMA; SIGNAL NOISE RATIO;

EID: 84898902599     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.02.031     Document Type: Article

References (61)

1. Peracaula R., Barrabes S., Sarrats A., Rudd P.M., de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Disease Markers 2008, 25:207-218.
2. Hochmeister M.N., Budowle B., Rudin O., Gehrig C., Borer U., Thali M., Dirnhofer R. Evaluation of prostate-specific antigen (PSA) membrane test assays for the forensic identification of seminal fluid. Journal of Forensic Sciences 1999, 44:1057-1060.
3. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. Journal of Clinical Oncology 2003, 21:383-391.
4. Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 2002, 59:797-802.
5. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer 2005, 5:845-856.
6. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J.J., Petros J.A., Andriole G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine 1991, 324:1156-1161.
7. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., Dekernion J.B., Ratliff T.L., Kavoussi L.R., Dalkin B.L., Waters W.B., Macfarlane M.T., Southwick P.C. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer - results of a multicenter clinical-trial of 6,630 men. Journal of Urology 1994, 151:1283-1290.
8. Bracarda S., de Cobelli O., Greco C., Prayer-Galetti T., Valdagni R., Gatta G., de Braud F., Bartsch G. Cancer of the prostate. Critical Reviews in Oncology/Hematology 2005, 56:379-396.
9. Laguna P., Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Current Opinion in Urology 2000, 10:3-8.
10. Barry M.J. Screening for prostate cancer - the controversy that refuses to die. New England Journal of Medicine 2009, 360:1351-1354.
11. Etzioni R., Gulati R., Cooperberg M.R., Penson D.M., Weiss N.S., Thompson I.M. Limitations of basing screening policies on screening trials. Medical Care 2013, 51:295-300.
12. Schroeder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A. Screening and prostate-cancer mortality in a randomized european study. New England Journal of Medicine 2009, 360:1320-1328.
13. Schroeder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Páez A., Maattanen L., Bangma C.H., Aus G., Carlsson S., Villers A., Rebillard X., van der Kwast T., Kujala P., Blijenberg B.G., Stenman U.H., Huber A., Taari K., Hakama M., Moss S.M., de Koning H.J., Auvinen A. Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine 2012, 366:981-990.
14. Roobol M.J., Kerkhof M., Schroeder F.H., Cuzick J., Sasieni P., Hakama M., Stenman U.H., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L., Recker F., Berenguer A., Ruutu M., Kujala P., Bangma C.H., Aus G., Tammela T.L.J., Villers A., Rebillard X., Moss S.M., de Koning H.J., Hugosson J., Auvinen A. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the european randomised study of screening for prostate cancer (ERSPC). European Urology 2009, 56:584-591.
15. Andriole G.L., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Gelmann E.P., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., Crawford E.D., O'Brien B., Clapp J.D., Rathmell J.M., Riley T.L., Hayes R.B., Kramer B.S., Izmirlian G., Miller A.B., Pinsky P.F., Prorok P.C., Gohagan J.K., Berg C.D. Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine 2009, 360:1310-1319.
16. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Isaacs C., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., O'Brien B., Ragard L.R., Clapp J.D., Rathmell J.M., Riley T.L., Hsing A.W., Izmirlian G., Pinsky P.F., Kramer B.S., Miller A.B., Gohagan J.K., Prorok P.C. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute 2012, 104:125-132.
17. Brawer M.K., Meyer G.E., Letran J.L., Bankson D.D., Morris D.L., Yeung K.K., Allard W.J. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998, 52:372-378.
18. Luderer A.A., Chen Y.-T., Soriano T.F., Kramp W.J., Carlson G., Cuny C., Sharp T., Smith W., Petteway J., Brawer M.K., Thiel R. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995, 46:187-194.
19. Catalona W.J., Southwick P.C., Slawin K.M., Partin A.W., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., Walsh P.C., Scardino P.T., Lange P.H., Gasior G.H., Loveland K.G., Bray K.R. Comparison of percent free, density, and age-specific cutoffs for prostate cancer detection and staging. Urology 2000, 56:255-260.
20. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., Katir D., Amirkhan A., Rittenhouse H.G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clinical Chemistry 2004, 50:1017-1025.
21. Sokoll L.J., Wang Y., Feng Z., Kagan J., Partin A.W., Sanda M.G., Thompson I.M., Chan D.W. [-2]Proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. Journal of Urology 2008, 180:539-543.
22. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews Cancer 2008, 8:268-278.
23. Saldova R., Fan Y., Fitzpatrick J.M., Watson R.W.G., Rudd P.M. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011, 21:195-205.
24. Sumi S., Arai K., Yoshida K. Separation methods applicable to prostate cancer diagnosis and monitoring therapy. Journal of Chromatography B 2001, 764:445-455.
25. Jankovic M.M., Kosanovic M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clinical Biochemistry 2005, 38:58-65.
26. Meany D.L., Zhang Z., Sokoll L.J., Zhang H., Chan D.W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. Journal of Proteome Research 2009, 8:613-619.
27. White K.Y., Rodemich L., Nyalwidhe J.O., Comunale M.A., Clements M.A., Lance R.S., Schellhammer P.F., Mehta A.S., Semmes O.J., Drake R.R. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. Journal of Proteome Research 2009, 8:620-630.
28. Li Y., Tian Y., Rezai T., Prakash A., Lopez M.F., Chan D.W., Zhang H. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Analytical Chemistry 2010, 83:240-245.
29. Sarrats A., Saldova R., Comet J., O'Donoghue N., de Llorens R., Rudd P.M., Peracaula R. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. Omics 2010, 14:465-474.
30. Tabares G., Jung K., Reiche J., Stephan C., Lein M., Peracaula R., de Llorens R., Hoesel W. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and Western blotting of immunopurified samples. Clinical Biochemistry 2007, 40:343-350.
31. Sarrats A., Comet J., Tabares G., Ramirez M., Aleixandre R.N., de Llorens R., Peracaula R. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Prostate 2010, 70:1-9.
32. Girard M., Lacunza I., Diez-Masa J.C., de Frutos M. Glycoprotein analysis by capillary electrophoresis. Handbook of Capillary and Microchip Electrophoresis and Associated Microtechniques 2008, CRC Press Inc., Boca Raton (Florida). Third Edition. J.P. Landers (Ed.).
33. Donohue M.J., Satterfield M.B., Dalluge J.J., Welch M.J., Girard J.E., Bunk D.M. Capillary electrophoresis for the investigation of prostate-specific antigen heterogeneity. Analytical Biochemistry 2005, 339:318-327.
34. Garrido-Medina R., Díez-Masa J.C., de Frutos M. CE methods for analysis of isoforms of prostate-specific antigen compatible with online derivatization for LIF detection. Electrophoresis 2011, 32:2036-2043.
35. Puerta A., Diez-Masa J.C., Martin-Alvarez P.J., Martin-Ventura J.L., Barbas C., Tuñon J., Egido J., de Frutos M. Study of the capillary electrophoresis profile of intact α-1-acid glycoprotein isoforms as a biomarker of atherothrombosis. Analyst 2011, 136:816-822.
36. Lucy C.A., MacDonald A.M., Gulcev M.D. Non-covalent capillary coatings for protein separations in capillary electrophoresis. Journal of Chromatography A 2008, 1184:81-105.
37. Drake R.R., White K.Y., Fuller T.W., Igwe E., Clements M.A., Nyalwidhe J.O., Given R.W., Lance R.S., Semmes O.J. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. Journal of Proteomics 2009, 72:907-917.
38. Pilch B., Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biology 2006, 7:R40.
39. Sensabaugh G.F., Blake E.T. Seminal plasma-protein P-30: simplified purification and evidence for identity with prostate-specific antigen. Journal of Urology 1990, 144:1523-1526.
40. Bindukumar B., Kawinski E., Cherrin C., Gambino L.M., Nair M.P.N., Schwartz S.A., Chadha K.C. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. Journal of Chromatography B 2004, 813:113-120.
41. Babu A.K.S., Vijayalakshmi M.A., Smith G.J., Chadha K.C. Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions. Journal of Chromatography B 2008, 861:227-235.
42. Peter J., Unverzagt C., Lenz H., Hoesel W. Purification of prostate-specific antigen from human serum by indirect immunosorption and elution with a hapten. Analytical Biochemistry 1999, 273:98-104.
43. Prakash S., Robbins P.W. Glycotyping of prostate specific antigen. Glycobiology 2000, 10:173-176.
44. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., Evans C.L., Gasior C.L., Linton H.J., Carpenter P., Rittenhouse H.G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Research 2001, 61:6958-6963.
45. Acevedo B., Perera Y., Torres E., Penton D., Ayala M., Gavilondo J. Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. Prostate 2006, 66:1029-1036.
46. Dwek M.V., Jenks A., Leathem A.J.C. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clinica Chimica Acta 2010, 411:1935-1939.
47. Perez L., Zulueta O., Melchor A., Hernandez L., Lopez R., Cazanave J., Bequer D. Purification of human prostatic-specific antigen (hPSA) from seminal plasma by immunoaffinity chromatography using a monoclonal antibody anti total PSA. Hybridoma 2011, 30:247-251.
48. Tabares G., Radcliffe C.M., Barrabes S., Ramirez M., Aleixandre R.N., Hoesel W., Dwek R.A., Rudd P.M., Peracaula R., de Llorens R. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006, 16:132-145.
49. de Frutos M., Molina E., Puerta A. Immunodetection of proteins in high-resolution separation systems. HPLC of Biological Macromolecules 2002, Marcel Dekker Inc., New York. second ed. K.M. Gooding, F.E. Regnier (Eds.).
50. Moser A.C., Hage D.S. Immunoaffinity chromatography: an introduction to applications and recent developments. Bioanalysis 2010, 2:769-790.
51. Phillips T.M. Immunoaffinity techniques in analysis. Journal of Chromatography B 2010, 878:113-114.
52. Ongay S., Lacunza I., Diez-Masa J.C., Sanz J., de Frutos M. Development of a fast and simple immunochromatographic method to purify alpha 1-acid glycoprotein from serum for analysis of its isoforms by capillary electrophoresis. Analytica Chimica Acta 2010, 663:206-212.
53. Ongay S., Neusuess C., Vaas S., Diez-Masa J.C., de Frutos M. Evaluation of the effect of the immunopurification-based procedures on the CZE-UV and CZE-ESI-TOF-MS determination of isoforms of intact alpha-1-acid glycoprotein from human serum. Electrophoresis 2010, 31:1796-1804.
54. Puerta A., Jaulmes A., De Frutos M., Diez-Masa J.C., Vidal-Madjar C. Adsorption kinetics of β-lactoglobulin on a polyclonal immunochromatographic support. Journal of Chromatography A 2002, 953:17-30.
55. Puerta A., Martin-Alvarez P.J., Ongay S., Diez-Masa J.C., de Frutos M. Immunoaffinity, capillary electrophoresis, and statistics for studying intact alpha 1-acid glycoprotein isoforms as an atherothrombosis biomarker. Clinical Applications of Capillary Electrophoresis. Methods in Molecular Biology Series 2013, Vol 919:215-230. Springer Protocols, Humana Press.
56. Puerta A., Diez-Masa J.C., de Frutos M. Immunochromatographic determination of beta-lactoglobulin and its antigenic peptides in hypoallergenic formulas. International Dairy Journal 2006, 16:406-414.
57. Puerta A., Diez-Masa J.C., de Frutos M. Use of immunodotting to select the desorption agent for immunochromatography. Journal of Immunological Methods 2004, 289:225-237.
58. Visser N., Lingeman H., Irth H. Sample preparation for peptides and proteins in biological matrices prior to liquid chromatography and capillary zone electrophoresis. Analytical and Bioanalytical Chemistry 2005, 382:535-558.
59. Concejero M.A., Galve R., Herradon B., Gonzalez M.J., de Frutos M. Feasibility of high-performance immunochromatography as an isolation method for PCBs and other dioxin-like compounds. Analytical Chemistry 2001, 73:3119-3125.
60. Yarmush M.L., Antonsen K.P., Sundaram S., Yarmush D.M. Immunoadsorption: strategies for antigen elution and production of reusable adsorbents. Biotechnology Progress 1992, 8:168-178.
61. Lara-Quintanar P., Lacunza I., Sanz J., Diez-Masa J.C., de Frutos M. Immunochromatographic removal of albuminin erythropoietin biopharmaceutical formulations for its analysis by capillary electrophoresis. Journal of Chromatography A 2007, 1153:227-234.